LEXX Key Statistics, Chart & Performance
The current stock price of LEXX is 0.6376 USD. In the past month the price decreased by -21.19%. In the past year, price decreased by -60.15%.
LEXX Technical Analysis
LEXX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LEXX. LEXX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LEXX Financial Highlights
Over the last trailing twelve months LEXX reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -14.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -178.37% | ||
| ROE | -219.69% | ||
| Debt/Equity | 0 |
LEXX Forecast & Estimates
7 analysts have analysed LEXX and the average price target is 4.59 USD. This implies a price increase of 619.89% is expected in the next year compared to the current price of 0.6376.
For the next year, analysts expect an EPS growth of 37.23% and a revenue growth 17.26% for LEXX
LEXX Ownership
LEXX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.25 | 969.015B | ||
| JNJ | JOHNSON & JOHNSON | 20.67 | 574.257B | ||
| MRK | MERCK & CO. INC. | 22.05 | 290.769B | ||
| PFE | PFIZER INC | 9.23 | 156.982B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.85 | 123.896B | ||
| ZTS | ZOETIS INC | 18.74 | 56.466B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.53 | 25.52B | ||
| VTRS | VIATRIS INC | 6.38 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.59 | 12.725B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.37 | 9.291B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LEXX
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Company Info
LEXARIA BIOSCIENCE CORP
100 - 740 Mccurdy Road
Kelowna BRITISH COLUMBIA V1X 2P7 CA
CEO: Christopher Bunka
Employees: 7
Phone: 12507656424
LEXARIA BIOSCIENCE CORP / LEXX FAQ
Can you describe the business of LEXARIA BIOSCIENCE CORP?
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
What is the current price of LEXX stock?
The current stock price of LEXX is 0.6376 USD. The price decreased by -6.47% in the last trading session.
Does LEXX stock pay dividends?
LEXX does not pay a dividend.
What is the ChartMill rating of LEXARIA BIOSCIENCE CORP stock?
LEXX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for LEXX stock?
7 analysts have analysed LEXX and the average price target is 4.59 USD. This implies a price increase of 619.89% is expected in the next year compared to the current price of 0.6376.
Can you provide the sector and industry classification for LEXARIA BIOSCIENCE CORP?
LEXARIA BIOSCIENCE CORP (LEXX) operates in the Health Care sector and the Pharmaceuticals industry.
Is LEXARIA BIOSCIENCE CORP (LEXX) expected to grow?
The Revenue of LEXARIA BIOSCIENCE CORP (LEXX) is expected to grow by 17.26% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.